The RNA Institute, University of Albany, State University of New York, Albany, New York 12222, United States.
ACS Sens. 2021 Sep 24;6(9):3176-3181. doi: 10.1021/acssensors.1c01567. Epub 2021 Sep 7.
Alzheimer's disease (AD) is the most common neurodegenerative disorder, with significant research efforts devoted to identifying new biomarkers for clinical diagnosis and treatment. MicroRNAs have emerged as likely disease regulators and biomarkers for AD, now implicated as having roles in several biological processes related to progression of the disease. In this work, we use the assay (croNA ctivated onditional ooping of ngineered witches) for single-step detection of AD-related microRNAs. The technology is based on conformationally responsive DNA nanoswitches that loop upon recognition of a target microRNA and report their on/off status through an electrophoretic readout. Unlike many methods, our approach directly detects native microRNAs without amplification or labeling, eliminating the need for expensive enzymes, reagents, and equipment. For known AD-related microRNA miR-107, we demonstrated sensitivity of ∼8 fM, specificity among four similar microRNAs of the same family, and simultaneous multiplexed detection of those four microRNA targets. Toward clinical use, we screened 56 AD-related microRNAs and found four that showed detectable differences between total RNA extracts derived from human healthy and AD brain samples. In the context of AD, this "smart reagent" could facilitate biomarker discovery, accelerate efforts to understand the role of microRNAs in AD, and have clinical potential as a diagnostic or monitoring tool for validated biomarkers.
阿尔茨海默病(AD)是最常见的神经退行性疾病,有大量研究致力于鉴定新的生物标志物用于临床诊断和治疗。microRNAs 可能是 AD 的疾病调节因子和生物标志物,现在被认为在与疾病进展相关的几个生物学过程中具有作用。在这项工作中,我们使用 assay(croNA ctivated onditional ooping of ngineered witches)用于 AD 相关 microRNAs 的一步检测。该技术基于构象响应性 DNA 纳米开关,在识别目标 microRNA 时会发生环化,并通过电泳读出报告其开/关状态。与许多方法不同,我们的方法直接检测天然 microRNAs,无需扩增或标记,从而消除了对昂贵酶、试剂和设备的需求。对于已知的 AD 相关 microRNA miR-107,我们证明了约 8 fM 的灵敏度、同一家族的四个类似 microRNAs 之间的特异性以及这四个 microRNA 靶标的同时多重检测。为了临床应用,我们筛选了 56 种 AD 相关 microRNAs,发现其中四种在源自人健康和 AD 大脑样本的总 RNA 提取物之间显示出可检测的差异。在 AD 中,这种“智能试剂”可以促进生物标志物的发现,加速对 microRNAs 在 AD 中的作用的理解,并具有作为经过验证的生物标志物的诊断或监测工具的临床潜力。